RESUMEN
Childhood trauma has been linked to schizophrenia, but underlying biological mechanisms remain elusive. This study explored the potential role of plasma oxytocin as a mediator in the relationship between childhood trauma and the psychopathology of schizophrenia. 160 patients with schizophrenia and 80 age- and sex-matched healthy controls were assessed for childhood trauma experiences using the Childhood Trauma Questionnaire and structured interviews. Psychopathology was evaluated using the Positive and Negative Syndrome Scale and plasma oxytocin levels were measured. Results showed that patients with schizophrenia had lower oxytocin levels and higher childhood trauma scores than healthy controls. There was a significant correlation between childhood trauma scores and psychopathology, with plasma oxytocin levels being inversely associated with psychopathology, except for positive symptoms. Hierarchical regression analysis indicated that both childhood trauma scores and plasma oxytocin levels significantly predicted psychopathology. Plasma oxytocin levels partially mediated the relationship between childhood trauma and schizophrenia psychopathology. This study underscores the potential role of oxytocin in bridging the gap between childhood trauma and schizophrenia.
RESUMEN
Concentrated suspensions of particles at volume fractions (Ï) ≥ 0.5 often exhibit complex rheological behavior, transitioning from shear thinning to shear thickening as the shear stress or shear rate is increased. These suspensions can be extruded to form 3D structures, with non-adsorbing polymers often added as rheology modifiers to improve printability. Understanding how non-adsorbing polymers affect the suspension rheology, particularly the onset of shear thickening, is critical to the design of particle inks that will extrude uniformly. In this work, we examine the rheology of concentrated aqueous suspensions of colloidal alumina particles and the effects of adding non-adsorbing polyvinylpyrrolidone (PVP). First, we show that suspensions with Ïalumina = 0.560-0.575 exhibited discontinuous shear thickening (DST), where the viscosity increased by up to two orders of magnitude above an onset stress (τmin). Increasing Ïalumina from 0.550 to 0.575 increased the viscosity and yield stress in the shear thinning regime and decreased τmin. Next, PVP was added at concentrations within the dilute and semi-dilute non-entangled regimes of polymer conformation (ÏPVP = 0.005-0.050) to suspensions with constant Ïalumina = 0.550. DST was observed in all cases and increasing ÏPVP increased the viscosity and yield stress. Interestingly, increasing ÏPVP also increased τmin. We posit that the free PVP chains act as lubricants between alumina particles, increasing the stress needed to induce thickening. Finally, we demonstrate through direct comparisons of suspensions with and without PVP how non-adsorbing polymer addition can extend the extrusion processing window due to the increase in τmin.
RESUMEN
AIMS: The aim of the meta-analysis of randomized controlled trials (RCTs) was to compare the effectiveness of glycemic control and hypoglycemia risk of combination therapy (metformin plus a low hypoglycemic risk antidiabetic drug) vs. standard metformin monotherapy, in patients with untreated type 2 diabetes mellitus (T2DM). METHODS: We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials through October 31, 2021 to find relevant RCTs. Efficacy outcomes were changes in hemoglobulin A1c (HbA1c) and fast plasma glucose (FPG) from baseline as well as proportion of patients achieving HbA1c < 7%; the safety outcome was hypoglycemia risk. RESULTS: We identified 14 RCTs comprising 5326 patients with untreated T2DM. Mean treatment duration was 28.1 weeks. Pooled results showed that compared to metformin monotherapy, combination therapy was associated with a reduction in HbA1c (mean difference: -0.48 %, -0.58 to - 0.38) and FPG (mean difference: -0.92 mmol/L, -1.14 to - 0.69), and more patients achieving HbA1c < 7% (odds ratio: 2.21, 1.87 to 2.60). Hypoglycemic events and people experiencing hypoglycemia were not different between 2 groups. CONCLUSIONS: Initial combination of metformin plus a low hypoglycemic risk antidiabetic drug may achieve better glycemic control, without a rise in hypoglycemia, in patients with untreated T2DM.
